Pulmatrix (PULM) Earning Somewhat Favorable Media Coverage, Report Shows
Media stories about Pulmatrix (NASDAQ:PULM) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pulmatrix earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 48.3034883602999 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Pulmatrix (NASDAQ:PULM) traded up $0.02 during trading on Tuesday, hitting $1.65. 235,600 shares of the stock were exchanged, compared to its average volume of 1,809,018. Pulmatrix has a one year low of $0.50 and a one year high of $6.98.
Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.08. The firm had revenue of $0.34 million for the quarter. research analysts predict that Pulmatrix will post -0.95 EPS for the current year.
Separately, Dawson James reiterated a “buy” rating on shares of Pulmatrix in a report on Wednesday, September 27th.
COPYRIGHT VIOLATION NOTICE: “Pulmatrix (PULM) Earning Somewhat Favorable Media Coverage, Report Shows” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://theolympiareport.com/2017/12/05/pulmatrix-pulm-earning-somewhat-favorable-media-coverage-report-shows.html.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.